Liminatus Pharma Inc. (NASDAQ:LIMN – Get Free Report) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 58,817 shares, a decline of 38.4% from the August 31st total of 95,505 shares. Based on an average daily volume of 27,526 shares, the short-interest ratio is currently 2.1 days. Currently, 5.4% of the shares of the company are short sold.
Liminatus Pharma Trading Down 0.8%
Shares of LIMN traded down $0.03 during mid-day trading on Thursday, hitting $3.70. 20,465 shares of the company’s stock were exchanged, compared to its average volume of 354,861. Liminatus Pharma has a fifty-two week low of $3.29 and a fifty-two week high of $141.50. The business’s 50 day moving average is $4.68 and its two-hundred day moving average is $7.07. The firm has a market capitalization of $4.96 million, a P/E ratio of -0.16 and a beta of 5.30.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the company. Wall Street Zen downgraded Liminatus Pharma to a “strong sell” rating in a research note on Saturday, August 22nd. Weiss Ratings cut Liminatus Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Liminatus Pharma currently has a consensus rating of “Sell”.
About Liminatus Pharma
Liminatus Pharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for serious diseases with significant unmet medical needs.
The company’s primary activities involve advancing pharmaceutical candidates through research and development, including preclinical and clinical testing. Publicly available information indicates that its work is centered on potential treatments in areas such as oncology and related therapeutic applications, rather than on marketed commercial products.
Liminatus Pharma is listed on the Nasdaq under the symbol LIMN.
Further Reading
- Five stocks we like better than Liminatus Pharma
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
- First Watch’s Growth Story Meets a Reality Check
- Down 50% and Climbing Again: 3 AI Stocks Rebuilding After Brutal Pullbacks
Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
